Roth MKM lowered the firm’s price target on Atlas Lithium to $39 from $47 and keeps a Buy rating on the shares. The price target decrease reflects lower spodumene price assumptions for 2025 and beyond, but Roth MKM believes investor interest could shift towards spodumene projects in the current price environment, the analyst says.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATLX: